Bio B2B 〉 Selective Search Results
Your Selection Setting ：North America；
Selective Search Results :
Pipeline & Platform 41 record(s)；
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
EG12014 Trastuzumab Biosimilar
Eirgenix aims to commercialize the first biosimilar product manufactured in Taiwan for the global market.Indication: HER2 Breast CancerExpected Product Launch: 2020Status: Phase 1 completed, BE established between EG12014 / EU & US HerceptinAdvantages of EG12014- The development of EG12014 follows EMA/FDA published guidance and past experience- EirGenix clinical study set up is considered an asset
Stabilized Injectable Formulation - SIF
The SIF drug delivery system consists of biodegradable materials dissolved in biocompatible solvents and a bioactive agent that is modified to achieve optimal formulation stability and release profile. The enhanced stability allows the formulation to be pre-filled into a ready-to-use syringe with a suitable storage shelf-life. The fill-finished product can be conveniently administered to patients via
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
Homogeneous antibody drugs (CHO-H01, H02, H03)
A unique glycan structure was identified for monoclonal antibodies with improved activity. With the proprietary technology developed by CHO Pharma, the Fc-glycan structure of therapeutic antibodies can be engineered to a homogeneous glycoform, which displayed enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC), in vivo anti-tumor activities, and potential anti-inflammatory properties
Small Molecule Drugs
ScinoPharm possesses a full range of chemistry capabilities and has extensive experience in synthesizing complex molecules. Depending on individual requirements, we develop new synthetic routes, or scale up and optimize processes based on the customer's technology. Our synthesis studies include structured Design of Experiment. (DoE) methods used to identify optimal conditions, factors that most
LT1001 is the first long-acting analgesic injection containing dinalbuphine sebacate, a prodrug of nalbuphine, in an oil-based formulation intended for sustained release of the drug. Nalbuphine is a κ-agonist / partial μ-antagonist analgesic with an analgesic effect comparable to that of morphine, yet it has a ceiling effect on respiratory depression. LT1001 was designed to take advantages
CVM-1118 is a small molecule NCE (new chemical entity). It has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM). CVM-1118 is currently being developed into a next generation oral anti-cancer drug. CVM-1118 has great potential showing inhibitory effect towards breast, ovarian, colon,
CHAP™ is a self-owned technology of SciVision Biotech Inc. which provides the unique viscoelasticity of HYADERMIS™ Facial Dermal Implant series and HYAJOINT Plus™ Synovial Fluid Supplement. CHAP™ gel with water-retention characteristic, acts as a kind of natural sponge. It creates volume in the tissue, lubricates, and transports nutrients to and from cells.
Core Technology: Pegylation PlatformIn the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting
Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.The patented Oradur® formulation
The PixoTest® technology utilizes the lighting and image sensing module of the smartphone (or mobile device) to detect the color change reaction on the biochemical test strip (US patent granted). The image of the test strip is captured by the front camera of the smartphone and analyzed via the measurement algorithm to turn out a quantified or semi-quantified result. With the control on light
The R&D Center has a testing center and various laboratories specializing in drug formulation, Chinese medicine, microorganisms, and cellular and molecular biochemical functions. By using precision instruments and technologies and gathering experts from different fields, the R&D Center offers a comprehensive range of services for product inspection, research and development, and improvement
Zwitterionic interface processing technology
Zwitterionic anti-fouling technologyTechnical seed development observed from the cell membrane phospholipid arrangement.It can be applied to various fields.Difficult to hydrolysis is a characteristic that make Zwitterionic better than traditionally used materials like PEG or HEMA. After surface modification using Zwitterionic technology the interface is endbow with highly biocompatible.
TAH9901 ADHD Trandermal Patch
TAH9901 comprise of a ADHD treatment proven to be safe and efficacious for over 50 years, and as a stimulant, is a first line therapy for children with ADHD. TAH 9901 offers a transdermal once daily treatment for ADHD.Uniqueness:• Reducing dosing frequency due to longer duration• Improved bioavailability• Uniform plasma levels, resulting in reduced side effect• Possibility of terminating
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
R17 is a new chemical entity in Taiwan for treating digestive system disease. It can improve the symptom of patients effectively and persistently. Developing of R17 is with high barrier of technology. After launching of R17, it will be a novel option in this disease field, and benefit lots of patients whose medical needs are not fulfilled.
New Chemical Entities - NCE
The up regulation of the proteolytic enzyme MMP-12 is implicated in many diseases, such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), acute lung injury (ALI), Alport syndrome (rare genetic kidney disease), atherosclerosis, ischemic retinopathy, wound healing, multiple sclerosis, cystic fibrosis, osteoarthritis, rheumatoid arthritis, allergic rhinitis, inflammatory bowel
LT3001 contains a new chemical entity which is composed of a thrombolytic polypeptide and a small molecule moiety with anti-oxidation activity. In rodent disease models where LT3001 was administered outside of the “golden (3) hours” post- stroke when tPA cannot be used, it significantly reduced brain infarction, restored blood flow and improved neuronal behavior score without hemorrhage
Burixafor( TG-0054) , is a novel, potent and selective chemokine receptor antagonist discovered by TaiGen. Burixafor rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation. Burixafor is currently in Phase 2 study in autologous stem cell transplantation in the US. Another Phase 2 study in chemosensitization is planned for China in 2015. Other potential
New combination for treating Sialorrhea
• Combination of two compounds with different Mechnism of Action to reduce the secreting of saliva.• First oral treatment for sialorrhoea of Parkinson's Disease.• Results of Phase IIa study, published in the 17th International Congress of Parkinson's Disease and Movement Disorders, shows efficacy and safety.
Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
CHO-A04 is a humanized monoclonal antibody targeting a novel carbohydrate antigen specifically and highly expressed on more than 10 cancer types, including triple negative breast cancer (TNBC) and pancreatic cancer. CHO-A04 kills cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The proof-of-concept (POC) study for CHO-A04 has been well
Cell selection adhesion technology
Cell selection adhesion technologyBase on the Zwitterionic coating surface, added with the charge-bias design, to have an effective resistance to various molecules include small-molecular, microorganisms Plankton and other cell adhesion, Further more gives the surface cell selection property.
TAH8801 Alzheimer's Disease Transdermal Patch
TAH8801 is a once a day transdermal patch system used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments. The patch releases medicine continuously over 24 hours. The medication is absorbed through the skin and may be an option for those who have trouble swallowing pills.Uniqueness• Reducing dosing frequency due to longer duration• Improved bioavailability&bull
Furaprevir (TG-2349) is a novel inhibitor of Hepatitis C virus (HCV) NS3/4A protease. This protease is essential for HCV replication and inhibitors have been shown to be effective in reducing viral load. TaiGen's goal is to develop a highly effective and affordable combination regimen with TG-2349 as the anchor.TG-2349 possesses the following unique characteristics that differentiate it from the competitors:Active
Poor solubility and high toxicity are significant problems with many new promising therapeutic approaches in oncology. By using TLC's lipid-based technology to improve solubility characteristics of a new derivative from a well-known chemotherapeutic drug (camptothecin), we were able to enhance its clinical development potential. In addition, TLC388 shows
SB01 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME, API and finished product manufactured to the USFDA IND. SB01 is an injectable anti-cancer NCE with multiple anti-tumor MOATreatement of cholangiocarcinoma has FDA Orphan Drug Designation clearancePhase I results show a favorable safety profilePhase II clinical trial of SB01 has
Isoniazid without liver toxicity
1. The common Tuberculosis (TB) drug Isoniazid has the most side effect of hepatotoxicity among all drugs, which is considered to be the major barrier of TB treatment.2. Isoniazid with new formulation has no hepatotoxicity due to the special excipient.
Dual-targeted bifunctional anti-flu drug (CHO-S05)
A novel series of dual-targeted bifunctional anti-flu drugs comprising of influenza virus inhibition and pro-inflammatory cytokine suppression are designed, synthesized and evaluated. In vitro and in vivo functional analyses have shown remarkable protection of cells and mice by oral administration against H1N1 & H5N1 influenza viruses.
TAH4411 Antiemetic Oral Thin Film
TAH4411 oral dissolving film (ODF) is a new formulation of a selective 5-HT3 receptor antagonist which blocks stimulation on both peripherally located vagal nerve terminals and centrally located receptors in the chemoreceptor trigger zone of the area postrema.This new formulation provides equivalent amount of the active ingredient as in Zofran® tablets and Zofran® OD tablets, but with a potential
Zelnite® Solution for Injection is developed for treatment or prevention of selenium deficiency that cannot be offset by intake from food sources, or in patients receiving parenteral nutrition.
TRIA11 is a biosimilar and its target indication is osteoporosis. This project is planned to launch at global market. In addition to drug development, we also develop an injection pen to increase the benefit of this product. Because this product has unique mechanism on osteoporosis treatment, its annual sales shows steady growth trend, and it is estimated up to $1.4 billion at global market.
TLC's own formulation of liposome encapsulated doxorubicin effectively reduces the side effects of doxorubicin and broadens its indications.
ScinoPharm provides comprehensive peptide synthesis technologies with full analytical and regulatory support. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, ScinoPharm can design and develop higher yield processes for larger-scale peptides that are scalable and more cost effective, ensuring faster time-to-market.Peptide Synthesis CapabilitiesSynthesis
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
Glycan arrays and glycoprobes
Synthetic oligosaccharides and/or polysaccharides are immobilized on a solid supported in a spatially-defined arrangement to mimic the glycan expression on cell surface. The arrays of various glycans can be used for the diagnosis and prognosis of the disease such as cancer and infectious disease. They can also be used as research tools such as the validation of glycan binding protein and antibody,
TAH9922 ADHD Oral Solution
TAH9922 is an once-daily, liquid ADHD treatment option. It is a flavored, immediate release ADHD treatment option for patients ages 6 and above. Dosing can be tailored to the treatment's need.Uniqueness:• Better Palatability• Improved patient compliance via non-invasive, painless and simple application
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.